# Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

> **NCT02628444** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 1050 (actual)

## Conditions studied

- Dengue Fever
- Dengue Hemorrhagic Fever

## Interventions

- **BIOLOGICAL:** CYD Dengue Vaccine
- **BIOLOGICAL:** Placebo (Sodium chloride 0.9%)

## Key facts

- **NCT ID:** NCT02628444
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-02
- **Primary completion:** 2020-04-29
- **Final completion:** 2020-04-29
- **Target enrollment:** 1050 (ACTUAL)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02628444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02628444, "Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02628444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*